ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
Adalimumab showed a similar safety profile in adolescents with moderate-to-severe HS as in adults, with better effectiveness data. .
Authors
- Ramón García Ruiz (ORCID: https://orcid.org/0000-0001-9087-4622)
- Cristina Ciudad
- J. Garcias‐Ladaria (ORCID: https://orcid.org/0000-0002-0831-9468)
- Ina Albert
- Eva Vilarrasa (ORCID: https://orcid.org/0000-0001-6507-0534)
- Mercè Grau‐Pérez (ORCID: https://orcid.org/0000-0002-7628-3495)
- Antonio Martorell (ORCID: https://orcid.org/0000-0003-1378-1590)
- Gemma Ochando
- Sofía Haselgruber (ORCID: https://orcid.org/0000-0002-8432-0954)
- Fernando Alfageme (ORCID: https://orcid.org/0000-0002-0962-9783)
- Raquel Rivera (ORCID: https://orcid.org/0000-0002-4604-0724)
- Alejandro Molina‐Leyva (ORCID: https://orcid.org/0000-0001-6882-2113)
- J.C. Pascual (ORCID: https://orcid.org/0000-0001-8279-215X)
- Minia Campos‐Domínguez (ORCID: https://orcid.org/0000-0002-4638-2265)
- Francisco Javier Melgosa
Institutions
- Hospital de Sant Pau (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital de Manises (ES)
- Hospital Universitario Doctor Peset (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Hospital Universitario Son Espases (ES)
Publication Details
- Journal
- Dermatology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1159/000546647
- Citations
- 1
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Celgene
- Galderma
- LEO Pharma
- Cilag